Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Alzheimer's disease Diagnosed by Infrared Analysis of Leucocytes

By LabMedica International staff writers
Posted on 13 Feb 2012
Infrared analysis of white blood cells may possibly be a promising way to diagnose Alzheimer's disease (AD) more accurately.

The technique, which is noninvasive, fast, and low-cost, measures how much infrared radiation is either emitted or absorbed by white blood cells and measured by spectroscopy. More...


Scientists at the Instituto de Estructura de la Materia (Madrid, Spain) used two-dimensional infrared spectroscopy to measure and compare the infrared radiation emitted or absorbed by the leucocytes of healthy controls, versus those of patients with mild, moderate, and severe Alzheimer's disease. A total of 50 patients with Alzheimer's and 20 healthy controls took part in the study and gave blood samples. The white blood cells or mononuclear leukocytes are thought to carry amyloid-ß peptide in Alzheimer patients.

The infrared spectrum of the film of leucocytes was measured with a 1725X spectrophotometer (Perkin-Elmer; Waltham, MA, USA) with high resolution and obtained as an average of 32 scans. The scientists found significant differences in the range of infrared wavelengths displayed between subjects, which were attributable to the different stages of formation of amyloid-ß structures in the blood cells. The results showed that, with this method, healthy controls could be distinguished from mild and moderate sufferers of Alzheimer's disease. The method is being explored as a tool for early diagnosis.

The analysis showed a good test performance: 90% sensitivity and 90.5% specificity for determinations involving mild and moderate AD patients and age-matched healthy controls, and 82.1% sensitivity and 90.5% specificity for determinations involving patients at the three AD stages, mild, moderate, and severe, and age-matched healthy controls. The study demonstrated that AD is associated with higher percentages of β-structure in mononuclear leukocytes than those in healthy age-matched controls.

The authors concluded that the method they used could potentially offer a more simple detection of alternative biomarkers of Alzheimer's disease. Mononuclear leukocytes seem to offer a stable medium to determine ß-sheet structure levels as a function of disease development. The measurements seem to be more sensitive for earlier stages of Alzheimer's disease, namely mild and moderate. The study was published online on January 21 2012, in the journal Analytical and Bioanalytical Chemistry.

Related Links:
Instituto de Estructura de la Materia
Perkin-Elmer



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated MALDI-TOF MS System
EXS 3000
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.